MS and Disability Progression in Latin America, Africa, Asia and the Middle East: A Systematic Review
Introduction
There is evidence of an increased prevalence and disease burden of Multiple Sclerosis (MS) in parts of the world where the risk was once considered low including: Latin America (LA), Middle East-North Africa (MENA), Sub-Saharan Africa and Asia (GBD 2016 Multiple Sclerosis Collaborators, 2019). The Global Burden of Disease (GBD) 2016 study group assessed percentage change in age-standardized Disability Adjusted Life Years related to MS between 1990 and 2016. Some of the largest increases in disability were seen in non-Western regions: Central LA: 37.3%; MENA: 16.1%; Sub-Saharan Africa: 11.0%; and South Asia: 19.4%. Age at onset, race and opticospinal MS (OSMS) presentation were identified as factors influencing progression in the clinical course of MS.
Regarding race, some reports showed that MS tends to be diagnosed earlier and is more aggressive among African Americans compared to Caucasians in the United States, reaching neurological disability levels more rapidly (Cree et al., 2004; Buchanan et al., 2004). Shifting to Europe, a study showed that people with MS (PwMS) living in France and of North African (NA) origin had more severe disability progression than French Caucasians (Debouverie et al., 2007).
In Eastern Asia, optico-spinal MS (OSMS) was proposed to be classified as ‘Asian-type MS’ (Kira et al., 1996), a disease with different clinical, radiological and immunological features compared to the so called ‘Western-type’ conventional MS (CMS). People with OSMS were found to reach disability milestones faster than their CMS counterparts, but also showed higher age at onset, a female sex preponderance, lower number of brain lesions and lower frequency of oligoclonal bands (OCBs) in the CSF (Kira J, 2003). OSMS had also been diagnosed in Southern Asia (Wasay et al., 2007), frequently in the MENA region (Yaqub, 1988) and less frequently in LA (Lana-Peixoto, 2008).
More recently, the discovery of anti-aquaporin 4 (AQP4) antibodies and the introduction of new diagnostic criteria for neuromyelitis optica (NMO) allowed the separation of OSMS into true MS cases with opticospinal presentation and cases belonging to the NMO spectrum (Wingerchuk et al., 2006). However, the debate on this topic is still active and many features of MS epidemiology in those regions where OSMS was more prevalent require a reassessment to better understand the MS phenotype.
Over the last two decades, many epidemiological studies have been performed in the majority world where the disease was historically less common. The purpose of the present review is to highlight the existing data on the MS clinical phenotypes and long-term morbidity in LA, Asia, Sub-saharan Africa and the MENA region.
Section snippets
Methods
A comprehensive literature review was conducted using several online databases including PubMed, SCOPUS, Global Health, and the Cochrane database from January 1st, 1980 to April 30th, 2020. A Boolean search was conducted using the same principles and terms between searches. All searches contained a variant of the following search terms: “Multiple Sclerosis AND (Phenotype OR Progression OR Disability OR Morbidity OR Longitudinal OR Expanded Disability Status Scale (EDSS) OR Clinical outcome OR
Results
We identified 1,604 peer-reviewed articles in our search of databases, then 35 additional studies from other sources. The search was narrowed to 1,094 unique articles once duplicates were removed and 579 of these were excluded after the first screening (Figure 1). A total of 515 articles were assessed full text for eligibility and 443 were excluded for: irrelevancy, wrong design, limited disease duration, small or non-MS patient sample, or foreign language. A total of 72 studies met the
Discussion
Our review of the long-term morbidity of MS in regions where the disease has been historically less studied has shown that the MS phenotype and progression is similar to the experience in Europe and North America. Our analysis reveals that MS can be defined by standardized criteria, and neurological disease progression is variable as assessed by MRI lesions and clinical morbidity outcomes.
We selected a few relevant studies on long-term MS morbidity from Western countries to allow comparison
Conclusion
The phenotype and disability progression of MS in LA, MENA, Asia and Sub-Saharan Africa have similarities to Western MS but in several regions take on a more aggressive course. MS progression is most rapid in MENA and selected LA regions where there are a high percentage of PwMS of African descent. Studies in Asia show mild to moderate progression when NMOSD cases are excluded from MS cohorts. In this region, the application of updated diagnostic criteria (Wingerchuck et al., 2015) and the
Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, or publication of this article.
Funding
This study was funded in part by the VA MS Center of Excellence-East. We are grateful to Elaine Sullo and the Himmelfarb Medical Library staff for their assistance on our review and development of the Covidence database. We also acknowledge the collaboration of Ho Kim, MD, PhD (Head, Department of Neurology, research Institute and Hospital, National Cancer Institute, Goyand, Korea) who provided additional data and assisted with data interpretation of the epidemiology of MS in Asia.
References (103)
- et al.
Magnetic resonance imaging markers of disability in Egyptian multiple sclerosis patients
Mult. Scler. Relat. Disord.
(2019) - et al.
Newly diagnosed multiple sclerosis in state of Qatar
Clin. Neurol. Neurosurg.
(2013) - et al.
Multiple sclerosis in Iraq: does it have the same features encountered in Western countries?
J. Neurol. Sci.
(2005) - et al.
Pediatric-Onset Multiple Sclerosis Disease Progression in Kuwait: A Retrospective Analysis
Pediatr. Neurol.
(2015) - et al.
Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review
J. Neurol. Sci.
(2009) - et al.
MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population
J. Neuroimmunol.
(2018) - et al.
Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese
Clin. Neurol. Neurosurg.
(2011) - et al.
Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese
J. Neuroimmunol.
(2013) - et al.
Western and Asian features of multiple sclerosis in Mexican Mestizos
Clin. Neurol. Neurosurg.
(2007) - et al.
CD24 as a genetic modifier of disease progression in multiple sclerosis in Argentinean patients
J. Neurol. Sci.
(2011)
Multiple Sclerosis in sub-Saharan Africa - a scoping review
Mult. Scler. Relat. Disord.
Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey
J Neurol Sci
Multiple sclerosis in the Japanese population
Lancet Neurol
Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings
J. Neurol. Sci.
chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis
J. Neuroimmunol.
Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
Mult. Scler. Relat. Disord.
Multiple sclerosis in Isfahan, Iran
Int. Rev. Neurobiol.
The influence of ethnicity on the characteristics of multiple sclerosis: a local population study between Persians and Arabs
Clin. Neurol. Neurosurg.
Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
J. Neurol. Sci.
Multiple sclerosis in India: An institutional study
Mult. Scler. Relat. Disord.
Evaluation of common mutations in the Mediterranean fever gene in Multiple Sclerosis patients: is it a susceptibility gene?
J. Neurol. Sci.
Predictors of progression in primary progressive multiple sclerosis in a large Turkish cohort
Mult. Scler. Relat. Disord.
Clinical characteristics of multiple sclerosis in Lebanon
J. Neurol. Sci.
Towards establishing a multiple sclerosis biobank in Jordan
Int. J. Neurosci.
The course of early-onset multiple sclerosis in Iraqi children
World. J. Pediatr.
Demographics and clinical characteristics of multiple sclerosis in Kuwait
Eur. Neurol.
Multiple sclerosis severity score in a cohort of Moroccan patients
Mult. Scler.
Comparison between multiple sclerosis in India and the United States: A case-control study
Neurology
Nursing home residents with multiple sclerosis: comparisons of African American residents to White residents at admission
Mult. Scler.
Multiple sclerosis in KwaZulu Natal, South Africa: An epidemiological and clinical study
Mult. Scler.
Clinical and epidemiological profile of multiple sclerosis in a reference center in the State of Bahia, Brazil
Arq. Neuropsiquiatr.
Clinical characteristics of multiple sclerosis in Taiwan: a cross-sectional study
Mult. Scler.
Multiple Sclerosis in the Asia Pacific Region: A Systematic Review of a Neglected Neurological Disease
Front. Neurol.
Long term outcome of multiple sclerosis in Asia
Neurology Asia
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis
Neurology
Long-term evolution of multiple sclerosis disability in the treatment era
Ann. Neurol.
Natural history of multiple sclerosis: a unifying concept
Brain
Ausencia de relación entre los genotipos de apolipoproteína E y la gravedad de la esclerosis múltiple en pacientes mexicanos [The absence of a relation between apolipoprotein E genotypes and the severity of multiple sclerosis in Mexican patients]
Rev. Neurol.
Multiple sclerosis in black South Africans and Zimbabweans
J. Neurol. Neurosurg. Psychiatry
More severe disability of North Africans vs Europeans with multiple sclerosis in France
Neurology
Clinical use of H1 MR spectroscopy in assessment of relapsing remitting and secondary progressive multiple sclerosis
EJRNM
Multiple sclerosis in Jordan: A clinical and epidemiological study
J. Neurol.
African ancestry is a predictor factor to secondary progression in clinical course of multiple sclerosis
ISRN Neurol
Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka
Mult. Scler. Int.
Global, regional, and national burden of multiple sclerosis 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016
Lancet Neurol.
Investigation of IL-21 gene polymorphisms (rs2221903, rs2055979) in cases with multiple sclerosis of Azerbaijan, Northwest Iran
Am. J. Clin. Exp. Immunol.
Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study
Neuropsychiatr. Dis. Treat.
Malignant multiple sclerosis: clinical and demographic prognostic factors
Arq. Neuropsiquiatr.
Cited by (2)
A national registry-based study of ethnic differences in people with multiple sclerosis in Iran
2024, Clinical Neurology and NeurosurgeryClinical and demographic profile of Ecuadorian patients with demyelinating diseases
2023, Neurologia Argentina